| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Completed Statistical Analyses of LEVEL Yielded a Predictive Enrichment Strategy Being Applied in Amended LEVEL-2 Protocol |
| 08 Oct 2026 |
8-K: Other Events
Forward-Looking Statements Disclaimers Except for historical information, all of the statements, expectations and assumptions contained in this presentation are forward-looking statements. These forward-looking statements include, but ar... |
| 09 Sep 2026 |
8-K: Regulation FD Disclosure
LEVEL Clinical Trial Results September 09, 2026 Exhibit 99.1 |
| 10 Aug 2026 |
8-K: Other Events
TNX-103 did not meet statistical significance on the primary endpoint of improvement in 6-minute walk |
| 31 Jul 2026 |
8-K: Results of Operations and Financial Condition
Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 |
| 02 Jul 2026 |
8-K: Other Events
Abstract recently submitted in anticipation of initial data analysis ahead of ESC |
| 30 Jun 2026 |
8-K: Entry into a Material Definitive Agreement
This sixth Amendment to the License Agreement of September 20, 2013 (hereinafter referred to as the “Amendment”) is made and executed as of this 29th day of June, 2026 (“Effective Date of Amendment”) by and between |
| 29 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
THIS FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”), is made as of June 29, 2026 by and between Tenax Therapeutics, Inc., a Delaware corporation, with its principal place of business in North Carolina (the “Company”... |
| 04 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 2, 2026, Tenax Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). The following proposals were voted upon at the Annual Meeting and the final voting results with respect to eac... |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
On track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026 |
| 22 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
This Executive Employment Agreement (this “Agreement”) is made as of April 9, 2026, by and between Tenax Therapeutics, Inc., a Delaware corporation, with its principal place of business in North Carolina (the “Company”), and Thomas R Sta... |
| 10 Mar 2026 |
8-K: Results of Operations and Financial Condition
Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 |
| 09 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
THIS SECOND AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”), is made as of January 6, 2026 by and between Tenax Therapeutics, Inc., a Delaware corporation, with its principal place of business in North Carolina (the “Compa... |
| 17 Dec 2025 |
8-K: Other Events
Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition
Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 |
| 16 Sep 2025 |
8-K: Other Events
Provides Patent Protection in Europe Through at Least December 2040 |
| 09 Sep 2025 |
8-K: Entry into a Material Definitive Agreement
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***].” |
| 13 Aug 2025 |
8-K: Results of Operations and Financial Condition
Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 |
| 17 Jun 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Tenax Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows: |
| 14 May 2025 |
8-K: Results of Operations and Financial Condition
Phase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026 |
Loading...